INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
ApexOnco Front Page
Recent articles
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
But camizestrant’s use could depend on uptake of monitoring – for now.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
Any hopes of differentiation could come down to side effects.
